Oncolytics Biotech Secures Key Patent for Pelareorep Manufacturing Through 2044
ONCY sits 61% above its 52-week low of $0.54.
Summary
Oncolytics Biotech secured a new U.S. patent protecting the commercial manufacturing process for its lead drug, pelareorep, until 2044. This strengthens the intellectual property estate for pelareorep, which has recently shown positive clinical data and received FDA alignment for a pivotal study. For a clinical-stage biotech with a 'going concern' warning and active capital raises, securing long-term IP protection for its primary asset is crucial. This patent de-risks the commercialization pathway and adds significant long-term value to pelareorep as it progresses towards potential market entry.
At the time of this announcement, ONCY was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.5M. The 52-week trading range was $0.54 to $1.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.